Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38results about How to "Promotes proliferation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Conditionally immortalized long-term stem cells and methods of making and using such cells
ActiveUS20070116691A1Inhibit apoptosisPromotes proliferationVirusesGenetic material ingredientsMyeloid leukemiaStudy methods
Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
Owner:UNIV OF COLORADO THE REGENTS OF +1
Conditionally immortalized long-term stem cells and methods of making and using such cells
ActiveUS20100297763A1Inhibit apoptosisPromotes proliferationVirus peptidesApoptosis related proteinsDiseaseStudy methods
Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
Owner:NAT JEWISH HEALTH +1
Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Integrin Receptor Antagonists and Their Methods of Use
ActiveUS20130129621A1Avoid blindnessAlleviate macular tractionAntibacterial agentsSenses disorderBinding siteAngiogenesis growth factor
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to α5β1-Integrin, αvβ3-Integrin and αvβ5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Owner:ALLEGRO PHARMA
Biomedical device, method for manufacturing the same and use thereof
InactiveUS20150004042A1Speed upIncrease volumeAdditive manufacturing apparatusLiquid surface applicatorsLead zirconate titanatePorosity
A method for manufacturing a three-dimensional biomedical device for fitting in a bone defect having an osteoinductive first area with a controlled porosity and a second area, which is produced by laser technology from an absorbent and from a first powder including one of ceramics, metals, metal alloys, bioactive glasses, lead zirconate titanate and biocompatible polymers, or mixtures thereof, wherein the ratio of the porosities from the second area to the first area is equal or less than one, preferably from 0.001 to 0.9, wherein a virtual object is designed with a computer-aid designed software, and the device is manufactured by laser technology including layering a powder onto a plate (7) so that a layer of a predetermined thickness is formed; the laser beam (8) selectively processes the powder to produce a processed layer, and, thus, layer after layer, the layers are joined together until the biomedical device is formed.
Owner:NIMAL DIDIER
Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
ActiveUS10064924B2Strong upregulationPromotes formationTumor rejection antigen precursorsHydrolasesHla class iiHuman tumor
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Peptide compositions and therapeutic uses thereof
ActiveUS9018352B2Promotes proliferationEasy SurvivalSenses disorderAntipyreticBinding siteAnimal subject
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Owner:ALLEGRO PHARMA
Methods and compositions for regenerating hair cells and/or supporting cells
InactiveUS20150209406A1Promotes cycle reentryPromotes proliferationSenses disorderNervous disorderVestibular dysfunctionCell cycle
Provided are methods and compositions for inducing cells of the inner ear (for example, cochlear and utricular hair cells) to reenter to cell cycle and to proliferate. More particularly, the invention relates to the use of agents that increase c-myc activity and / or Notch activity for inducing cell cycle reentry and proliferation of cochlear or utricular hair cells and / or cochlear or utricular supporting cells. The methods and compositions can be used to promote the proliferation of hair cells and / or supporting cells to treat a subject at risk of or affected with, hearing loss or a subject at risk of or affected with vestibular dysfunction.
Owner:MASSACHUSETTS EYE & EAR INFARY
Integrin receptor antagonists and their methods of use
ActiveUS9896480B2Promotes proliferationEasy SurvivalAntibacterial agentsSenses disorderBinding siteNK1 receptor antagonist
Owner:ALLEGRO PHARMA
Stem and progenitor cell expansion by evi, evi-like genes and setbp1
InactiveUS20090028836A1Increasing cell proliferationEfficient deliveryBiocideVirusesActivation methodPRDM16
A method of increasing cell proliferation by modulating levels of EVI and related genes. Activation of EVI-1, PRDM16, or SETBP1 can increase the proliferation rate, self renewal and / or in vitro and / or in vivo survival and / or engraftment of human cells, either in vitro or in vivo. The gene modulation can be performed by various means, including traditional cloning methods and retroviral-based gene activation methods. The method can also be used to more efficiently deliver gene-corrected cells to a patient in need of treatment.
Owner:KALLE CHRISTOF VON +2
Collagen/hydroxyapatite composite scaffold, and process for the production thereof
ActiveUS8435552B2High mechanical stiffnessIncrease stiffnessPowder deliveryPeptide/protein ingredientsCross-linkCompressive stiffness
A process for producing a collagen / hydroxyapatite (HA) composite scaffold comprises the steps of forming a homogenous suspension of collagen and HA in an acidic solution, lyophilizing the suspension until a desired final freezing temperature is reached to produce the composite scaffold, and optionally cross-linking the composite scaffold, wherein the ratio of HA to collagen is at least 1:10 (w / w). Also provided is a collagen / hydroxyapatite (HA) composite scaffold comprising a homogenous distribution of hydroxyapatite within a porous, crosslinked, collagen matrix, wherein the ratio of HA to collagen is at least 1:10 (w / w). Suitably, the composite scaffold has a porosity of at least 99% (v / v), and a compressive stiffness of at least 0.3 KPa. Composite scaffolds of the invention may be used to provide osteoconductive bone implants and tissue engineering implants.
Owner:ROYAL COLLEGE OF SURGEONS & IRELAND
Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
ActiveUS20110182989A1Avoid blindnessAlleviate macular tractionSenses disorderAntipyreticBinding siteCysteic acid
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Owner:ALLEGRO PHARMA
Portable disposable re-usable culture device for rapid diagnosis of infectious agents
ActiveUS20160304827A1Promotes proliferationImprove stabilityBioreactor/fermenter combinationsBiological substance pretreatmentsMicroorganismMicrobiology
Owner:VAX IMMUNE LLC
Cell cycle regulation and differentiation
InactiveUS20090258423A1Promote differentiationPromotes differentiationNervous disorderBiological material analysisNeural cellCell cycle
The present invention provides compositions and methods for regulating neural cell proliferation or differentiation. The present invention also provides methods for selecting for bioactive agents effective in regulating proliferation or differentiation.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method for culturing neural stem cells using hepatocyte growth factor
InactiveUS20060134078A1Increase in sizeIncrease the number ofBiocideNervous disorderNeurulationCell culture media
A medium containing hepatocyte growth factor (HGF) was shown to induce neurosphere formation. Furthermore, the addition of HGF to a culture medium containing FGF-2, EGF, or both increased both the size and number of newly formed neurospheres. Thus, the present invention relates to a growth medium comprising HGF for culturing neural stem cells and methods for culturing the cells using the culture medium.
Owner:ANGES MG INC
Peptide therapies for reduction of macular thickening
ActiveUS20210002328A1Promotes proliferationEasy SurvivalSenses disorderSamplingBinding sitePharmaceutical medicine
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to α5β1-Integrin, αvβ3-Integrin and αvβ5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Owner:ALLEGRO PHARMA
Chimeric antigen receptor containing a toll-like receptor intracellular domain
ActiveUS20170233454A1Increasing tumor immunological effect effectGood treatment effectAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenRegulatory T cell
The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and / or Toll-like receptor 2 intracellular domain(s); compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.
Owner:SHENZHEN IN VIVO BIOMEDICINE TECH LTD
Genome editing of human neural stem cells using nucleases
InactiveUS20170298348A1Promotes proliferationImprove viabilitySenses disorderNervous disorderGenome editingPharmaceutical drug
The invention provides methods for generating a genetically modified human neural stem cell, genetically modified human neural stem cells, and pharmaceutical compositions comprising the genetically modified human neural stem cells. Also provided are associated kits. The invention also provides methods for preventing or treating a neurodegenerative disease or a neurological injury in a human subject using genetically modified human neural stem cells.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Chimeric antigen receptor containing a toll-like receptor intracellular domain
ActiveUS10093717B2Function increaseReduce immunosuppressionAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenRegulatory T cell
Owner:SHENZHEN IN VIVO BIOMEDICINE TECH LTD
Methods for generation of antibodies
ActiveUS8551968B2Promotes proliferationEasy SurvivalSsRNA viruses negative-senseGenetic material ingredientsAntigenAntibody-Producing Cells
Owner:REFAELI YOSEF +2
Portable disposable re-usable culture device for rapid diagnosis of infectious agents
ActiveUS20160348056A1Prevent escapePromotes proliferationBioreactor/fermenter combinationsBiological substance pretreatmentsMicroorganismInfectious agent
Owner:VAX IMMUNE LLC
Portable disposable re-usable culture device for rapid diagnosis of infectious agents
ActiveUS20180291327A1Prevent escapePromotes proliferationBioreactor/fermenter combinationsBiological substance pretreatmentsMicroorganismInfectious agent
Owner:VAX IMMUNE LLC
Dual functional novel peptide having cell permeability and bone tissue regeneration ability, and use thereof
ActiveUS20190382446A1Improve abilitiesEfficient use ofPeptide/protein ingredientsAntibody mimetics/scaffoldsPeptideOsteoporosis
The present invention relates to a novel peptide derived from the copine 7 protein and having both cell permeability and bone tissue regeneration ability, and to a use of the peptide. The peptide according to the present invention has excellent bone tissue regeneration ability and is therefore useful for treating a disease requiring bone regeneration, such as osteoporosis. Particularly, by also having cell permeability, the peptide does not require the attachment of a separate peptide or addition of another preparation for the cell permeation thereof and thus can be conveniently applied in orthopedics and the like requiring various surgical regeneration treatments.
Owner:SEOUL NAT UNIV R&DB FOUND +1
HIP1 cancer markers
ActiveUS20030124533A1Altered expressionReducing growth factor dependenceSugar derivativesMicrobiological testing/measurementDrugProstate
The present invention relates to compositions and methods for cancer diagnostics and therapeutics, including but not limited to, HIP1 cancer markers. In particular, the present invention provides compositions and methods of using HIP1 in the diagnosis and treatment of epithelial cancers. The present invention thus provides improved compositions and methods for diagnosing and treating some of the most common cancers (e.g., prostate and colon cancers). The present invention additionally provides drugs active against HIP1 and methods for screening for such drugs.
Owner:THE RGT OF THE UNIV OF MICHIGAN
Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
ActiveUS20190275130A1Strong upregulationPromotes formationTumor rejection antigen precursorsHydrolasesHla class iiHuman tumor
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Single domain antibodies that bind to cd137
PendingUS20200362047A1Enhanced maturationImprove presentationImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseCD137
The disclosure relates to CD137 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
Owner:CRESCENDO BIOLOGICS
Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
ActiveUS8883507B2Inhibit apoptosisPromotes proliferationVirusesImmunological disordersCell differentationBlood-forming stem cell
Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
Owner:TAIGA BIOTECHNOLOGIES (ABC) LLC +2
Binding molecules
PendingUS20220220215A1Enhanced maturationImprove presentationAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsCD137Antiendomysial antibodies
The disclosure relates to multispecific agents that simultaneously bind CD137 and PD-1 and which comprise a single domain antibody specific to CD137 and a moiety that binds PD-1, for example a single domain antibody. The disclosure also relates to therapeutic and diagnostic applications of such agents, for example in the treatment of a cancer.
Owner:CRESCENDO BIOLOGICS
Composition, comprising aucklandia lappa decne. extract, for preventing hair loss or promoting hair regrowth
PendingUS20220233623A1Promote growthPromote proliferationDermatological disorderFood ingredient functionsPharmaceutical SubstancesBotany
Disclosed herein are a composition comprising an Aucklandia lappa Decne. extract, especially a crude solvent extract from Aucklandia lappa as an active ingredient for alleviation, inhibition, prevention, or treatment of hair loss, and a preparation method therefor. The Aucklandia lappa Decne. extract can be used in a pharmaceutical or food composition useful for alleviating, inhibiting, preventing, and treating hair loss.
Owner:OKCHUNDANG
Biomedical device, method for manufacturing the same and use thereof
InactiveUS9889012B2Dissipate itSimple processAdditive manufacturing apparatusLiquid surface applicatorsPorosityLead zirconate titanate
A method for manufacturing a three-dimensional biomedical device for fitting in a bone defect having an osteoinductive first area with a controlled porosity and a second area, which is produced by laser technology from an absorbent and from a first powder including one of ceramics, metals, metal alloys, bioactive glasses, lead zirconate titanate and biocompatible polymers, or mixtures thereof, wherein the ratio of the porosities from the second area to the first area is equal or less than one, preferably from 0.001 to 0.9, wherein a virtual object is designed with a computer-aid designed software, and the device is manufactured by laser technology including layering a powder onto a plate (7) so that a layer of a predetermined thickness is formed; the laser beam (8) selectively processes the powder to produce a processed layer, and, thus, layer after layer, the layers are joined together until the biomedical device is formed.
Owner:NIMAL DIDIER
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com